RU2754466C2 - Слитый полипептид с противораковой активностью - Google Patents

Слитый полипептид с противораковой активностью Download PDF

Info

Publication number
RU2754466C2
RU2754466C2 RU2017135539A RU2017135539A RU2754466C2 RU 2754466 C2 RU2754466 C2 RU 2754466C2 RU 2017135539 A RU2017135539 A RU 2017135539A RU 2017135539 A RU2017135539 A RU 2017135539A RU 2754466 C2 RU2754466 C2 RU 2754466C2
Authority
RU
Russia
Prior art keywords
ser
val
leu
lys
gly
Prior art date
Application number
RU2017135539A
Other languages
English (en)
Russian (ru)
Other versions
RU2017135539A3 (enExample
RU2017135539A (ru
Inventor
Марлон ХИННЕР
АЙБА Рачида Сихам БЕЛ
Кристине РОТЕ
Шейн ОЛЬВИЛЛЬ
Коринна ШЛОССЕР
Original Assignee
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ filed Critical ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ
Publication of RU2017135539A publication Critical patent/RU2017135539A/ru
Publication of RU2017135539A3 publication Critical patent/RU2017135539A3/ru
Application granted granted Critical
Publication of RU2754466C2 publication Critical patent/RU2754466C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
RU2017135539A 2015-05-18 2016-05-18 Слитый полипептид с противораковой активностью RU2754466C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15167927 2015-05-18
EP15167927.1 2015-05-18
EP16150508 2016-01-08
EP16150508.6 2016-01-08
PCT/EP2016/061071 WO2016184882A1 (en) 2015-05-18 2016-05-18 Anti-cancer fusion polypeptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021119777A Division RU2021119777A (ru) 2015-05-18 2016-05-18 Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения

Publications (3)

Publication Number Publication Date
RU2017135539A RU2017135539A (ru) 2019-06-18
RU2017135539A3 RU2017135539A3 (enExample) 2019-11-29
RU2754466C2 true RU2754466C2 (ru) 2021-09-02

Family

ID=56134305

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017135539A RU2754466C2 (ru) 2015-05-18 2016-05-18 Слитый полипептид с противораковой активностью
RU2021119777A RU2021119777A (ru) 2015-05-18 2016-05-18 Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021119777A RU2021119777A (ru) 2015-05-18 2016-05-18 Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения

Country Status (22)

Country Link
US (2) US10913778B2 (enExample)
EP (2) EP4219535A1 (enExample)
JP (1) JP6947642B2 (enExample)
KR (1) KR102685748B1 (enExample)
CN (1) CN108112253B (enExample)
AU (1) AU2016262845B2 (enExample)
CA (1) CA2980838A1 (enExample)
DK (1) DK3298030T5 (enExample)
ES (1) ES2938525T3 (enExample)
FI (1) FI3298030T3 (enExample)
HR (1) HRP20230145T1 (enExample)
HU (1) HUE061108T2 (enExample)
LT (1) LT3298030T (enExample)
MX (1) MX390894B (enExample)
PL (1) PL3298030T3 (enExample)
RS (1) RS64002B1 (enExample)
RU (2) RU2754466C2 (enExample)
SG (1) SG11201707426SA (enExample)
SI (1) SI3298030T1 (enExample)
SM (1) SMT202300026T1 (enExample)
WO (1) WO2016184882A1 (enExample)
ZA (1) ZA201706061B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
US11261221B2 (en) * 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN108348573A (zh) 2015-07-15 2018-07-31 皮里斯制药有限公司 Lag-3特异性的新型蛋白
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA3047070A1 (en) * 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
WO2018127710A1 (en) 2017-01-06 2018-07-12 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
MX2019008434A (es) * 2017-01-18 2019-11-11 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina con afinidad de unión por lag-3.
WO2018134279A1 (en) * 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
CN111683968B (zh) 2017-11-13 2024-07-05 克雷森多生物制剂有限公司 结合至cd137和psma的分子
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN112004535A (zh) 2018-03-26 2020-11-27 4Sc股份公司 用于癌症疗法的包括hdac抑制剂和cd137激动剂的组合
AU2019315703A1 (en) * 2018-07-31 2020-12-10 Les Laboratoires Servier Novel fusion protein specific for CD137 and PD-L1
US12486330B2 (en) * 2019-02-26 2025-12-02 Pieris Pharmaceuticals Gmbh Fusion proteins specific for CD137 and GPC3
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
EP3952996A1 (en) * 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
TW202337914A (zh) * 2019-04-23 2023-10-01 南韓商Ｌｇ化學股份有限公司 融合多肽及其用途與製備方法、核酸分子、重組載體、重組細胞以及用於增強生長/分化因子15或其功能變體的活體內穩定性的方法
PE20220231A1 (es) * 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
TW202428603A (zh) * 2022-09-21 2024-07-16 美商思進公司 新穎的cd137及cd228特異性融合蛋白

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376316C2 (ru) * 2003-10-10 2009-12-20 Бристол-Маерс Сквибб Компани Человеческие антитела против человеческого 4-1вв (cd137)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
WO1995031479A1 (en) 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
PL192364B1 (pl) 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
EP1430136A1 (en) 2001-09-27 2004-06-23 Pieris ProteoLab AG Muteins of apolipoprotein d
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
AU2007280398B2 (en) 2006-08-01 2012-05-10 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN101516907B (zh) 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
RS54624B1 (sr) 2007-07-17 2016-08-31 E. R. Squibb & Sons, L.L.C. Monoklonska antitela protiv glipikana-3
CA2702590A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Glycosylated mammalian ngal and use thereof
EP2313430B1 (en) 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
US9549968B2 (en) 2009-12-07 2017-01-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 (LcnC,hNGAL) with affinity for a given target
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
DK2640740T3 (en) 2010-11-15 2017-06-26 Pieris Pharmaceuticals Gmbh MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
US20140179560A1 (en) * 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN104140974B (zh) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
AU2015205530B8 (en) * 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
SG10201906859PA (en) 2015-01-28 2019-08-27 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
AR103714A1 (es) 2015-02-18 2017-05-31 Sanofi Sa Proteínas específicas para pioverdina y pioquelina
US11261221B2 (en) * 2015-05-04 2022-03-01 Pieris Pharmaceuticals Gmbh Proteins specific for CD137
CN107636014B (zh) 2015-05-04 2021-12-07 皮里斯制药有限公司 抗癌融合多肽
CN107787327B (zh) 2015-05-18 2022-02-08 皮里斯制药有限公司 对磷脂酰肌醇聚糖-3（gpc3）具有亲和力的人脂质运载蛋白2的突变蛋白
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2376316C2 (ru) * 2003-10-10 2009-12-20 Бристол-Маерс Сквибб Компани Человеческие антитела против человеческого 4-1вв (cd137)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JAKUBOVICH BD, JOTHY S "Glypican-3: From the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma", Experimental and Molecular Pathology, 2007, Vol. 82, pp. 184-189. *
SKERRA A "‘Anticalins’: a new class of engineered ligand-bindingproteins with antibody-like properties", Reviews in Molecular Biotechnology, 2001, Vol. 74, pp. 257-275. *
SKERRA A "‘Anticalins’: a new class of engineered ligand-bindingproteins with antibody-like properties", Reviews in Molecular Biotechnology, 2001, Vol. 74, pp. 257-275. JAKUBOVICH BD, JOTHY S "Glypican-3: From the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma", Experimental and Molecular Pathology, 2007, Vol. 82, pp. 184-189. *
WYZGOL A et. al. "Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand", J Immunology, 2009, Vol. 183, No. 3, pp. 1851-1861. *

Also Published As

Publication number Publication date
HRP20230145T1 (hr) 2023-04-28
KR20180002855A (ko) 2018-01-08
LT3298030T (lt) 2023-02-27
EP3298030B1 (en) 2023-01-18
RU2017135539A3 (enExample) 2019-11-29
AU2016262845A1 (en) 2018-01-04
SMT202300026T1 (it) 2023-03-17
MX390894B (es) 2025-03-21
CN108112253B (zh) 2022-09-23
US20210403516A1 (en) 2021-12-30
KR102685748B1 (ko) 2024-07-18
ES2938525T3 (es) 2023-04-12
EP3298030A1 (en) 2018-03-28
HUE061108T2 (hu) 2023-05-28
FI3298030T3 (fi) 2023-02-22
DK3298030T5 (en) 2024-10-07
SI3298030T1 (sl) 2023-05-31
RU2017135539A (ru) 2019-06-18
WO2016184882A1 (en) 2016-11-24
CN108112253A (zh) 2018-06-01
AU2016262845B2 (en) 2020-07-23
JP6947642B2 (ja) 2021-10-13
DK3298030T3 (en) 2023-02-06
SG11201707426SA (en) 2017-10-30
US10913778B2 (en) 2021-02-09
CA2980838A1 (en) 2016-11-24
RU2021119777A (ru) 2021-08-16
MX2017014716A (es) 2018-06-28
ZA201706061B (en) 2022-05-25
EP4219535A1 (en) 2023-08-02
RS64002B1 (sr) 2023-03-31
US20180148485A1 (en) 2018-05-31
US11919931B2 (en) 2024-03-05
PL3298030T3 (pl) 2023-05-08
JP2018519803A (ja) 2018-07-26
BR112017020445A2 (pt) 2018-07-03

Similar Documents

Publication Publication Date Title
RU2754466C2 (ru) Слитый полипептид с противораковой активностью
US20210198380A1 (en) Anti-cancer fusion polypeptide
JP7476219B2 (ja) Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
RU2628699C2 (ru) Trail r2-специфические мультимерные скаффолды
JP7482488B2 (ja) Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質
JP2025532652A (ja) Ｃｄ１３７およびｃｄ２２８に特異的な新規融合タンパク質
RU2818349C2 (ru) Новый слитый белок, специфичный для cd137 и pd-l1
EA046634B1 (ru) Новый слитый белок, специфичный к cd137 и pd-l1
HK40053668A (en) Novel fusion protein specific for cd137 and pd-l1
HK1249526B (en) Anti-cancer fusion polypeptide
BR112017020445B1 (pt) Proteína de fusão, molécula de ácido nucleico, célula hospedeira, método de produção de uma proteína de fusão, uso de uma ou mais proteínas de fusão e composição farmacêutica